Clinical Trial Update: Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating atezolizumab after surgery to prevent recurrence in patients with early-stage non-small cell lung cancer (AASI-NSCLC) is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Non-Small Cell Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING